Emerging data demonstrate important roles for the TYRO3/AXL/MERTK receptor tyrosine kinase (TAM RTK) family in diverse cancers. We investigated the prognostic relevance of GAS6 expression, encoding the common TAM RTK ligand, in 270 adults (n ¼ 71 agedo60 years; n ¼ 199 aged X60 years) with de novo cytogenetically normal acute myeloid leukemia (CN-AML). Patients expressing GAS6 (GAS6 þ ), especially those aged X60 years, more often failed to achieve a complete remission (CR). In all patients, GAS6 þ patients had shorter disease-free (DFS) and overall (OS) survival than patients without GAS6 expression (GAS6 À ). After adjusting for other prognostic markers, GAS6 þ predicted CR failure (P ¼ 0.02), shorter DFS (P ¼ 0.004) and OS (P ¼ 0.04). To gain further biological insights, we derived a GAS6-associated gene-expression signature (Po0.001) that in GAS6 þ patients included overexpressed BAALC and MN1, known to confer adverse prognosis in CN-AML, and overexpressed CXCL12, encoding stromal cell-derived factor, and its receptor genes, chemokine (C-X-C motif) receptor 4 (CXCR4) and CXCR7. This study reports for the first time that GAS6 expression is an adverse prognostic marker in CN-AML. Although GAS6 decoy receptors are not yet available in the clinic for GAS6 þ CN-AML therapy, potential alternative therapies targeting GAS6 þ -associated pathways, for example, CXCR4 antagonists, may be considered for GAS6 þ patients to sensitize them to chemotherapy.
INTRODUCTION
Constitutive activity of the receptor tyrosine kinase (RTK) family has been observed in malignant blasts from patients with acute myeloid leukemia (AML). Members of the RTK family include FLT3 and KIT, whose constitutive kinase activity can occur through several mechanisms, such as mutationally induced autophosphorylation, receptor overexpression and/or aberrant expression of the receptors' ligands. [1] [2] [3] The constitutive activity of FLT3 and KIT has been associated with poor clinical outcomes, and therapeutic targeting of activated RTKs is currently an area of intense investigation. [4] [5] [6] [7] [8] In cancer, another RTK family, the TAM RTKs (that is, TYRO3, AXL and MERTK), has been shown to support survival, proliferation, migration, invasion, angiogenesis, metastasis and chemoresistance, [9] [10] [11] [12] and TAM RTK inhibitors are already in pre-clinical and clinical development for several solid tumors. [11] [12] [13] Although TAM RTKs are aberrantly expressed in AML, 11, 14, 15 to date, only AXL expression has been reported to adversely impact outcome in adults with cytogenetically normal AML (CN-AML). 16 No AXL mutations have been described in AML, suggesting that activation of AXL may occur at least in part via aberrant autocrine expression of GAS6, which binds AXL with high affinity and is also the common ligand for all three TAM RTKs. 17 GAS6 was shown to be aberrantly expressed in AML cell lines. 18 These data point to a possible role for the GAS6/TAM RTK signaling axis in AML and prompted us to test the clinical impact of GAS6 expression in a molecularly characterized cohort of chemotherapy-treated adults with de novo CN-AML.
MATERIALS AND METHODS Patients
Available pretreatment bone marrow (BM) or blood samples were obtained from 270 patients with de novo CN-AML (aged 18-83 years; median, 66 years; n ¼ 71 aged o60 years; n ¼ 199 aged X60 years) enrolled on Cancer and Leukemia Group B (CALGB)/Alliance companion protocols 8461 (cytogenetic analyses), 20202 (molecular analyses) and 9665 (tissue banking). Patients were treated on CALGB/Alliance protocols 8525, 8923, 9420, 9720, 10201 or 19808. [19] [20] [21] [22] [23] [24] [25] The treatment protocols included cytarabine/daunorubicin-based induction but differed with regard to consolidation therapy (for details, see Supplementary Material). Per protocols, no patient received allogeneic stem-cell transplantation in first complete remission (CR). All protocols were in accordance with the Declaration of Helsinki and approved by the institutional review boards at each center, and all patients provided written informed consent.
Cytogenetic and molecular analyses
For the patient's karyotype to be considered normal, X20 metaphases from short-term cultures of the BM specimens obtained at diagnosis had to have been analyzed and the normal result confirmed by central karyotype review. 26 Tissue samples were cryopreserved after mononuclear cell enrichment through a Ficoll gradient. The presence or absence of FLT3 internal tandem duplication (FLT3-ITD), 27 FLT3 tyrosine kinase domain mutations, 28 MLL partial tandem duplication, 29, 30 39 and MN1 40 expression levels were assessed centrally as previously described. Patients were also categorized according to the European LeukemiaNet (ELN) reporting system. 41 CN-AML patients with CEBPA mutation and/or NPM1 mutation without FLT3-ITD were classified in a Favorable Genetic Group and those with wild-type CEBPA, FLT3-ITD and/ or NPM1 mutation or wild-type NPM1 in an Intermediate-I Genetic Group.
Expression analysis of GAS6 and TAM RTKs GAS6, TYRO3, AXL and MERTK transcript expression levels were measured with Affymetrix U133 plus 2.0 array (Affymetrix, Santa Clara, CA, USA) assays. The GeneAnnot chip definition file was used to derive a single expression value for each gene per patient sample. 42 For array normalization and expression value computation, the robust multichip average method was implemented separately for samples from older and younger patients. 43 Patients were categorized as either expressing GAS6 (yes or GAS6-positive, hereafter denoted GAS6 þ ) if the probe-set fluorescence intensity (PFI) was greater than background fluorescence intensity (BFI) and not expressing GAS6 (no or GAS6-negative denoted GAS6 À ) if the GAS6 PFI was pBFI. Similarly, patients were categorized as either TYRO3 þ or AXL þ (if the PFIs were 4BFI) and TYRO3 À or AXL À (if the PFIs were pBFI). The MERTK PFI was above the BFI in all samples, and based on an optimal cutpoint analysis (see Supplementary Material), 44 patients were grouped into high expressers (MERTK þ ) or low expressers (MERTK À ) if they were in the upper two tertiles or in the lowest tertile groups, respectively.
Affymetrix-microarray gene-expression profiling analysis
To establish a signature of genes differentially expressed between GAS6 þ and GAS6 À patients, we evaluated the aforementioned Affymetrix geneexpression profiles. Normalized expression values were compared between GAS6 þ and GAS6 À patients, and a univariable significance level of Po0.001 was used to identify differentially expressed genes. A global test of significance based on a permutation procedure was performed to determine whether or not the number of differentially expressed genes was more than expected by chance. The false discovery rate was used to assess multiple testing errors. A permutation test was computed based on 1000 random permutations.
The Ingenuity Pathway Analysis tool (IPA Tool; Ingenuity H Systems, Redwood City, CA, USA; http://www.ingenuity.com) was used to identify enriched biological networks, global functions and functional pathways. Genes with altered expression profile associated with GAS6 expression status were imported into the IPA Tool. As a second means for identifying enriched ontologies, the web-based Database for Annotation, Visualization, and Integrated Discovery (DAVID) tool (DAVID Bioinformatics resources 6.7 http://david.abcc.ncifcrf.gov/) was used.
Clinical end points and statistical analyses Baseline characteristics were compared between GAS6 þ and GAS6 À patients using the Fisher's exact test for categorical variables and the Wilcoxon's rank-sum test for continuous variables. Definitions of clinical end points (that is, CR, disease-free (DFS) and overall (OS) survival) and details of outcome analyses are provided in the Supplementary Material. Briefly, for time-to-event analyses we calculated survival estimates using the Kaplan-Meier method 45 and compared groups by the log-rank test. We constructed age group-adjusted multivariable logistic regression models to analyze factors associated with the achievement of CR and age groupadjusted multivariable Cox proportional hazards models 46 for factors associated with survival end points. All analyses were performed by the Alliance for Clinical Trials in Oncology Statistics and Data Center.
RESULTS
Association of GAS6 expression status with clinical characteristics, TAM RTK expression status and molecular markers at diagnosis Of the 270 patients, 26% of patients were GAS6 þ (n ¼ 69) and 74% were GAS6 À (n ¼ 201). At diagnosis, GAS6 þ patients had higher platelet counts (P ¼ 0.03), lower percentages of blood blasts (P ¼ 0.01), more often hepatomegaly (P ¼ 0.006) and co-expression of AXL (28 vs 5%, Po0.001) compared with GAS6 À patients. There was no association between GAS6 and TYRO3 expression (P ¼ 0.74), whereas more GAS6 À than GAS6 þ patients were MERTK þ (P ¼ 0.02, Table 1 ). Compared with GAS6 À patients, GAS6 þ patients were more often wild type for NPM1 (Po0.001) and CEBPA (P ¼ 0.02) and therefore more often in the ELN Intermediate-I Genetic Group (Po0.001) and had mutations in RUNX1 (Po0.001) and ASXL1 (P ¼ 0.002) and high BAALC (P ¼ 0.02) and MN1 (P ¼ 0.05; Table 1 ) expression.
Impact of GAS6 expression on clinical outcomes of de novo CN-AML patients In age group-adjusted analyses, GAS6 þ expression associated with lower odds of achieving CR (Po0.001; Table 2 ), with CR rates significantly different in patients aged X60 years (46% GAS6 þ (n ¼ 54) vs 74% GAS6 À (n ¼ 145); Po0.001). None of the TAM RTKs impacted on CR (Supplementary Table S1 ). To assess whether GAS6 expression independently affects clinical outcomes when other known clinical and molecular prognostic features are considered, we performed multivariable analyses. For CR, GAS6 þ status predicted lower probability of achieving CR ((P ¼ 0.02; odds ratio, 0.46; 95% confidence interval (CI), 0.23-0.89)), after adjusting for the ELN CN-AML Genetic Group 41 status, BAALC expression status, white blood cell count and age group (Table 3) .
GAS6 þ expression associated with shorter DFS (P ¼ 0.03) and OS (P ¼ 0.004) compared with GAS6 À patients ( Table 2 and Figure 1 ). As single markers, neither AXL nor MERTK influenced DFS or OS, whereas TYRO3 expression adversely impacted on both end points (Supplementary Table S1 ). In multivariable modeling for DFS and OS, we noted a significant interaction (DFS, P ¼ 0.01; OS, P ¼ 0.04) between GAS6 expression and the combined TYRO3 and AXL expression status. In the dual receptor-positive patients, that is, positive for one or both TYRO3 and AXL expression, GAS6 expression did not independently impact outcome, which may be reflective of the interplay between the GAS6 ligand and the TYRO3 and AXL receptors (Table 3 ). In the dual receptor-negative patients, that is, negative for both TYRO3 and AXL expression, GAS6 expression remained an independent, adverse prognostic marker. Within the subgroup of dual receptor-negative patients, GAS6 þ expression was a predictor of shorter DFS (P ¼ 0.004; hazard ratio (HR) ¼ 2.12; 95% CI, 1.27-3.56) after adjusting for WT1 and DNMT3A R882 mutations, BAALC expression and age group; and shorter OS (P ¼ 0.04; HR ¼ 1.55; 95% CI, 1.01-2.38) after adjusting for ELN group, WT1 and DNMT3A R882 mutations, BAALC expression, white blood cell count and age group.
A GAS6-associated gene-expression signature in de novo CN-AML To gain additional molecular insights into GAS6 þ CN-AML, an Affymetrix microarray-based gene-expression signature was derived. The signature contained 1238 genes that were significantly differentially expressed between GAS6 þ and GAS6 À CN-AML blasts at diagnosis (Supplementary Table S2 ). Within this signature, genes for which high expression level is an established adverse prognosticator in CN-AML were BAALC and MN1. These were overexpressed, respectively, 2.57-fold and 2.41-fold in the GAS6 þ subgroup. Although hitherto not validated in large, independent patient sets, overexpression of the following four genes was reported to have an impact on outcome of AML patients. These were APP, which encodes the amyloid precursor protein and whose overexpression was associated with shorter GAS6 expression in adults with acute myeloid leukemia SP Whitman et al All patients with GAS6 probe-set fluorescence intensity greater than the background fluorescence intensity (BFI) are defined as GAS6-positive (GAS6 þ ) and those with GAS6 probe-set intensity pBFI as GAS6-negative (GAS6 À ). Similarly, patients were categorized as either TYRO3 þ (TYRO3 expression 4BFI) or TYRO3 À (if TYRO3 expression was pBFI) and AXL þ (expression 4BFI) or AXL À (expression pBFI). If a patient has AXL þ and TYRO3 þ expression, AXL þ and TYRO3 À expression or AXL À and TYRO3 þ expression, then TYRO3/AXL dual receptor is defined to be positive. If a patient has AXL À and TYRO3 À expression, then TYRO3/ AXL dual receptor is defined to be negative. e According to the ELN recommendations, 41 Favorable Genetic Group is defined as CEBPA mutated or FLT3-ITD negative and NPM1 mutated. Intermediate-I Genetic Group is defined as CEBPA wild type and FLT3-ITD positive and NPM1 mutated, FLT3-ITD negative and NPM1 wild type, or FLT3-ITD positive and NPM1 wild type.
f The median expression value was used as the cutoff for high and low values.
GAS6 expression in adults with acute myeloid leukemia SP Whitman et al survival than that of AML patients without APP overexpression 47 (overexpressed 3.37-fold in GAS6 þ patients); SETBP1, whose overexpression leads to PP2A inhibition, promoting proliferation of leukemic cells 48 (overexpressed 1.73-fold); SPARC, which is overexpressed in patients with IDH2-R172 mutations and contributes to AML aggressiveness 49 (overexpressed 2.05-fold); and CD74, whose lower surface protein levels associated with achievement of CR/partial CR in AML patients aged 60-75 years treated with bortezomib in combination with chemotherapy (overexpressed 2.51-fold). 50 Moreover, overexpressed in GAS6 þ CN-AML diagnostic samples were CXCL12 (3.2-fold), encoding for stromal cell-derived factor-1, and genes encoding both of its receptors, chemokine (C-X-C motif) receptor 4 (CXCR4; 1.52-fold) and CXCR7 (1.72-fold). Overexpression of CXCR4 has been previously associated with adverse clinical outcome in patients with CN-AML. 51, 52 CEBPA was among the 611 genes underexpressed in GAS6 þ patients; mutations in the CEBPA gene that encodes a transcription factor are associated with better outcome of AML patients (Supplementary Table S2). 32 CD33, encoding an immunotherapeutic target in AML, was also underexpressed (1.67-fold) in GAS6 þ patients.
Gene-expression signatures were not identified for any of the TAM RTKs (o10 genes, with false discovery rates of 10%; data not shown). Indeed, there was no apparent contribution from TAM RTKs in profiling analyses combining GAS6 with each of the TAM RTKs. This indicates that it is GAS6 expression status that drives the differential gene expression we observed.
Pathway analysis revealed that the GAS6-associated geneexpression signature contained the following overrepresented molecular and cellular functions: (a) cell cycle, (b) cellular growth and proliferation, (c) cell death and survival, (d) cellular assembly and organization, and (e) DNA replication, recombination and Abbreviations: CI, confidence interval; ELN, European LeukemiaNet; HR, hazard ratio; OR, odds ratio; WBC, white blood cell. Note: ORs 4(o) 1.0 mean a higher (lower) complete remission rate, and HRs 4(o) 1.0 mean higher (lower) risk for the higher values of the continuous variables and the first category listed for the categorical variables. Variables considered were those significant at a ¼ 0.20 in univariable models, that is, for complete remission, GAS6 ( þ vs À ), ELN (Favorable vs Intermediate-I), WT1 (mutated vs wild type), ASXL1 (mutated vs wild type), ERG (high vs low), BAALC (high vs low), platelet counts (50 Â 10 9 /l increase), WBC count (50 Â 10 9 /l increase), extramedullary involvement (present vs absent), and age group (X60 years vs o60 years); for disease-free survival, GAS6 ( þ vs À ), TYRO3/AXL dual receptor status ( þ vs À ), ELN (Favorable vs Intermediate-I), WT1 (mutated vs wild type), MLL-PTD (present vs absent), DNMT3A (R882 mutated vs non-R882 mutated and wild type), ERG (high vs low), BAALC (high vs low), and age group (X60 years vs o60 years); for overall survival, GAS6 ( þ vs À ), TYRO3/AXL dual receptor status ( þ vs À ), ELN (Favorable vs Intermediate-I), WT1 (mutated vs wild type), MLL-PTD (present vs absent), RUNX1 (mutated vs wild type), DNMT3A (R882 mutated vs non-R882 mutated and wild type), ERG (high vs low), BAALC (high vs low), WBC count (50 Â 10 9 /l increase), and age group (X60 years vs o60 years).
a According to the European LeukemiaNet (ELN) recommendations, 41 Favorable Genetic Group is defined as CEBPA mutated or FLT3-ITD negative and NPM1 mutated. Intermediate-I Genetic Group is defined as CEBPA wild type and FLT3-ITD positive and NPM1 mutated, FLT3-ITD negative and NPM1 wild type or FLT3-ITD positive and NPM1 wild type.
b Median cut was used to determine whether patients were in the high or low expression group.
GAS6 expression in adults with acute myeloid leukemia SP Whitman et al repair ( Table 4 ). The top canonical pathways included (a) interleukin-8 signaling, (b) growth hormone signaling, (c) mitotic roles of Polo-like kinase, (d) CXCR4 signaling, and (e) Tec kinase signaling (Table 4) . Of the top upstream regulators, colonystimulating factor 2 (granulocyte-macrophage) was predicted by IPA to be activated, whereas the cyclin-dependent kinase inhibitor CDKN1A was predicted by IPA to be inhibited (Table 4) . A second analysis using DAVID also identified enriched clusters of genes, with the most highly enriched cluster (score of 9.66; Benjamini corrected P-values ranging from 2.8E-9 to 3.5E-6) containing genes involved in the cell cycle (data not shown).
DISCUSSION
We report herein that GAS6 expressed by AML blasts is a marker of poor clinical outcomes in adults with CN-AML, independent of other established prognostic markers in this cytogenetic subset. Not only does GAS6 expression predict CR failure, albeit driven by older age, it has also a negative impact on DFS and OS in the studied cohort. The multivariable analyses revealed the negative prognostic impact of GAS6 was in patients whose leukemic blasts did not express TYRO3 and AXL. This suggests that GAS6 may contribute to a more aggressive disease through signaling mechanisms that are not dependent on AXL and TYRO3 expression within the AML cells. Perhaps, it is the third GAS6 receptor MERTK that together with GAS6 has a role within the TYRO3 À /AXL À patient subgroup. Based on recently published data related to MERTK function in leukemia, MERTK, even when expressed at relatively low levels, appears to contribute to a leukemic phenotype.
14 However, in the current study, a too low number of patients prohibited a reliable GAS6/MERTK subgroup analyses.
Given that GAS6 expression has an adverse impact on CR achievement, mainly in older patients, and on DFS and OS in all patients, this warrants development of novel, less toxic and perhaps more personalized therapies targeting GAS6. We recently reported that blocking the engagement of GAS6 to the AXL receptor with soluble AXL-Fc chimeric protein inhibits downstream signal transduction, inducing differentiation and apoptosis in human AML cell lines and patient samples with activated AXL. 53 Consistent with our work, 53 a recent study by Ben-Batalla et al., 54 showed that pharmacological inhibition of GAS6/AXL signaling induces leukemic cell death. We did not find an impact of AXLpositive expression as a sole marker on outcomes in our study, whereas AXL expression above the median was associated with shorter OS in the study by Ben-Batalla et al. 54 This may be explained in part by therapy differences and differences in patient cohort characteristics. Their study exclusively analyzed adult patients aged p60 years, whereas 73% of patients in our study were aged X60 years.
As our study measured GAS6 transcript levels, the relationship between GAS6 mRNA, protein and secretion in AML is not yet clear. However, there are several studies of various solid cancers that report that GAS6 mRNA and protein are present within the tumor cells. For example, Buehler et al. 55 recently reported that GAS6 mRNA and the translated protein are both elevated within ovarian cancer. Additionally, GAS6 mRNA and protein levels were found in 81% and 74% of glioblastoma multiforme tissue samples, suggesting a close 1:1 relationship between transcription and translation of GAS6. 56 As for secretion, Ben-Batalla et al.
54
performed immunohistochemistry for GAS6 on five AML patients' BMs and concluded that stromal cells are the primary source of secreted GAS6 ligand ( Figure 1 and Supplementary Table 3 in the article by Ben-Batalla et al. 54 ). Interaction of the GAS6/TAM RTK signaling axis with the stromal microenvironment in solid tumors has been associated with poor progression-free survival. 57, 58 A similar mechanism may be active in chemotherapy-resistant AML patients that express GAS6. This suggests a potential for novel therapies targeting GAS6 þ leukemic blasts that could also simultaneously inhibit negative b Significant values shown indicate the range of P-values for each of the genes that were identified within each of the annotated functions listed.
GAS6 expression in adults with acute myeloid leukemia SP Whitman et al effects of GAS6 in the microenvironment, ultimately improving patient survival. Promising studies using decoy receptors showed significant activity against the growth of lung carcinoma cells in a xenograft model, 13 and the absence of toxicity in normal murine tissues or hematopoiesis is encouraging. 59 Given our current findings, GAS6-targeted therapeutic agents could lead to higher CR rates, particularly, as our data indicate, benefiting older patients, and possibly prolonging survival of the GAS6 þ subset of CN-AML patients. Furthermore, while our results await independent validation, development of GAS6 decoy receptors, in addition to selective small molecule TAM inhibitors, appears warranted.
Meanwhile, in the short term, one possibility for improving outcomes of GAS6 þ patients is alluded to by the GAS6-associated gene-expression signature we identified. Overexpression of CXCR4 and its ligand was detected in pretreatment samples from patients expressing GAS6. In separate reports, overexpression of this signaling axis associated with increased risk of relapse and shorter OS in AML. 51, 52 CXCR4 is expressed on normal hematopoietic stem cells and regulates stem cell homing and retention in the BM when CXCL12, produced by BM stroma, engages the receptor. 60 The CXCR4 antagonist, Plerixafor, currently has FDA (Food and Drug Administration) approval in combination with granulocyte colony-stimulating factor as a stem cell mobilizing agent for patients with multiple myeloma and non-Hodgkin lymphoma who undergo autologous hematopoietic stem cell transplantation. 61 Uy et al. 62 recently reported their results of a phase I/II clinical trial that demonstrated antagonizing the CXCL12/CXCR4 axis with Plerixafor induces chemosensitization of relapsed or refractory AML blasts. Thus, although GAS6 decoy receptors are not yet available in the clinic for GAS6 þ CN-AML therapy, potential alternative therapies such as CXCR4 antagonists should be considered for GAS6 þ patients to sensitize them to chemotherapy.
